IP Library Patent Application 13563822
Patent Application
App. No. 13/563,822

Stepwise Process for the Production of Alkaloid Salts

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/563,822
Abstract

The present invention provides to an improved process for preparing alkaloid salts. In particular, the process comprises a stepwise addition of an acid to an alkaloid chosen from hydrocodone, codeine, and dihydrocodeine to form a flowable mixture of the alkaloid salt.

Claims (21)

1 . A process for the production of alkaloid salts, the process comprising a stepwise addition of an acid to an alkaloid, wherein the alkaloid is chosen from hydrocodone, codeine, or dihydrocodeine, and the process results in a flowable mixture of the alkaloid salt.

2 . The process of claim 1 , wherein the acid is chosen from acetic, adipic, alginic, ascorbic, aspartatic, benzenesulfonic, benzoic, camphoric, capric, caprylic, carbonic, citric, cyclamic, dodecylsulfuric, ethanesulfonic, ethane-1,2-disulfonic, fumaric, galactaric, gentisic, glucoheptanoic, gluconic, glucuronic, glutamic, glutaric, glycolic, glycerophosphoric, hippuric, hydrochloric, hydrobromic, hydroxy, isobutyric, lactic, lactobioni, lauric, maleicm, malonic, methanesulfonic, malic, naphthalene-1,5-disulfonic, naphthalene-2-sulfonic, 2-napthoic 1-hydroxy, nicotinic, oleic, orotic, 2-oxo glutaric, oxalic, palmitic pamoic, propionic, pyroglutamic, phosphoric, sebacic, succinic, sulfuric, tartaric, and thiocyanic, p-toluenesulfonic acids, and stearic acid.

3 . The process of claim 1 , wherein the process further comprises a solvent system.

4 . The process of claim 3 , wherein the solvent system comprises an organic solvent.

5 . The process of claim 4 , wherein organic solvent is chosen from methanol, ethanol and isopropanol.

6 . The process of claim 3 , wherein the solvent system further comprises water.

7 . The process of claim 6 , wherein water comprises about 10 to about 13% of the total solvent system.

8 . The process of claim 1 , wherein the stepwise addition comprises a first portion of about 40% to about 60% of the acid, and subsequent portions range from about 10% to about 20% of the acid.

9 . The process of claim 1 , wherein the stepwise addition comprises a first portion of about 60% of the acid with subsequent portions of about 10% of the acid.

10 . The process of claim 1 , wherein the stepwise addition comprises a first portion of about 55% of the acid with subsequent portions of about 10% of the acid.

11 . The process of claim 1 , wherein the stepwise addition comprises a first portion of about 50% of the acid with subsequent portions of about 10% of the acid.

12 . The process of claim 1 , wherein the process is conducted at a temperature ranging from about 50° C. to about 70° C.

13 . The process of claim 12 , wherein the reaction mixture is cooled to a temperature below about 25° C. to form a flowable alkaloid salt mixture.

14 . The process of claim 1 , wherein the ratio between the amine group of the alkaloid and the acid is about 1:1.1, respectively.

15 . The process of claim 1 , wherein the alkaloid salt is produced in a yield above about 90%.

16 . The process of claim 3 , wherein the acid is tartaric acid, the alkaloid is chosen from hydrocodone and dihydrocodeine, and the solvent system is comprised of methanol, ethanol, and water.

17 . The process of claim 3 , wherein the acid is phosphoric acid, the alkaloid is codeine, and the solvent system is comprised of methanol, ethanol, and water.

18 . A process for the production of hydrocodone bitartrate wherein the process comprises the following steps:

a. adding about 0.4 equivalents of tartaric acid to a mixture of 1 equivalent of hydrocodone in about 85% ethanol, 5% methanol, and about 10% water, and stirring the mixture for about 1 hour;

b. adding about 0.1 equivalents of tartaric acid to the mixture and stirring for about 1 hour; and

c. repeating step (b) until about 1.1 equivalents of tartaric acid have been added to the reaction to result in a flowable mixture of hydrocodone bitartrate.

Assignments (3)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2012
From: JONES, BRADLEY R.; HAAR, JOSEPH P., JR.; ROESCH, KEVIN R.; VANDERKOLK, LESLIE L.
To: MALLINCKRODT LLC
Reel/Frame 028693/0529 →